온라인상담

궁금하신점을 빠르고 정확한 상담으로 도와드리겠습니다.

카톡상담신청

전화번호를 남겨주시면 카카오톡 상담으로 도와드리겠습니다.

이   름       

연락처    - -

상담내용

개인정보취급방침    개인정보취급방침 동의

오시는길

주소 : 서울시 서초구 효령로 431
청화빌딩 2층 강남푸른숲한의원



진료안내




닫기

부작용완화

항암 부작용 완화


한방관리를 통한 항암 부작용 완화


1. Platin계열 (알킬화 약물) 항암제의 부작용

골수기능
장애
구역과
구토
구내염
설사
변비 색소
침착
말초
신경염
정신
장애
간장애 신장애
섬유화
심장
장애
출혈성
방광염
탈모 신경계
부작용
사이클로포스파마이드
(Cytoxan)
이포스파마이드
(Ifex)
시스플라틴
(Cis-DDP)
카보플라틴
(Cis-DpⅡ)
옥실리플라틴
(eloxatin)

 


Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer

Abstract
Peripheral neurotoxicity is the major limiting factor for oxaliplatin therapy. Goshajinkigan (GJG), a traditional Japanese herbal medicine, was recently shown to be effective in protecting against the neurotoxicity of taxanes in Japan. We retrospectively investigated the effect of GJG on peripheral neurotoxicity associated with oxaliplatin therapy. Ninety patients with metastatic colorectal cancer that received FOLFOX4 or modified FOLFOX6 therapy were assigned to receive one of the following adjuncts: oral GJG at 7.5 g day^<−1> (Group A, n = 11), intravenous supplementation of calcium gluconate and magnesium sulfate (1 g each before and after FOLFOX) (Group B, n = 14), combined GJG and calcium gluconate and magnesium sulfate therapies (Group C, n = 21), or no concomitant therapy (Group D, n = 44). The incidence of peripheral neurotoxicity was investigated when the cumulative dose of oxaliplatin exceeded 500 mgm^<−2>.When the cumulative dose of oxaliplatin exceeded 500 mgm^<−2>, the incidence of neuropathy (all grades) in Groups A-Dwas 50.0%, 100%, 78.9%, and 91.7%, respectively. It was lowest in the group that received GJG alone. Concomitant administration of GJG reduced the neurotoxicity of oxaliplatin in patients that received chemotherapy for colorectal cancer.

진행-전이성 대장암에서 옥살리플라틴과 함께 한약을 투여받은 환자 군에서 옥살리플라틴만 투여받은 환자군보다 말초신경 증상이 더 적게 나타났다는 연구결과 입니다.


02. 5-FU계열 (항대사 약물) 항암제의 부작용

골수기능
장애
구역과
구토
구내염
설사
변비 색소
침착
말초
신경염
정신
장애
간장애 신장애
섬유화
심장
장애
출혈성
방광염
탈모 신경계
부작용
메소트렉세이트
(MTX)
플루오로우라실
(5-FU)
카페시타빈
(Xeloda)
젬시타빈
(Gemzar)

 


Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect

Abstract
TS-1 is an oral anticancer drug containing a 5-fluorouracil derivative (Tegafur) that is widely used in Japan for the treatment of cancer, especially gastrointestinal tumors. Frequently, however, TS-1 therapy has to be discontinued because of leukopenia. If it were possible to predict the development of bone marrow suppression before the white blood cell (WBC) count had actually decreased, treatment could be improved by strict dosage control and/or the prophylactic administration of hematopoietic drugs. Juzentaihoto (JTT), a traditional Japanese medicine (Kampo), has been reported to activate hematopoiesis and reduce the side effects associated with chemotherapy and radiotherapy. Here, we 1) evaluate the efficacy of JTT in alleviating myelosuppression induced by TS-1 therapy in mice, and 2) explore biomarkers that reflect both induction by TS-1 and alleviation by JTT of bone marrow suppression using a proteomics approach

5-FU 계열의 항암제인 TS-1에 의해 발생하는 골수기능억제를 한약 투여를 통해 완화시킬 수 있다는 연구결과 입니다.


03. Taxane계열 (천연물질 기반) 항암제의 부작용

골수기능
장애
구역과
구토
구내염
설사
변비 색소
침착
말초
신경염
정신
장애
간장애 신장애
섬유화
심장
장애
출혈성
방광염
탈모 신경계
부작용
파클리탁셀
(Taxol)
도세탁셀
(Taxotere)
에토포사이드
(VP-16)
이리노테칸
(Camprosar)
톡소루비신
(Adriamycin)

 


Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer

Purpose
Kampo medicine Hangeshashin-to (TJ-14) which contains baicalin, a β-glucuronidase inhibitor, alleviates diarrhea induced by irinotecan (CPT-11). We conducted a randomized comparative trial to investigate whether support with TJ-14 would prevent and control CPT-11-induced diarrhea.

Methods
Of 44 previously untreated patients with advanced non-small-cell lung cancer randomized, 41 (18 TJ-14 group, 23 control group) were available for evaluation. The chemotherapy regimen consisted of a combination of cisplatin and CPT-11. TJ-14 (7.5 g/day) was administered orally.

이리노테칸 부작용으로 발생한 설사의 제어에 한약투여가 도움이 되었다는 내용과 탁솔에 의한 말초신경병증이 한약의 투여를 통해 완화되었다는 내용의 논문입니다.


04. 표적치료 항암제의 부작용

골수기능
장애
구역과
구토
구내염
설사
변비 색소
침착
말초
신경염
정신
장애
간장애 신장애
섬유화
심장
장애
출혈성
방광염
탈모 신경계
부작용
트라스투주압
(Herceptin)
이마티닙
(Gleevec)
게피티닙
(Iressa)
에로티닙
(Tarceva)

 


Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia

Abstract
During imatinib therapy, many patients with chronic myeloid leukemia (CML) develop severe neutropenia, leading to treatment interruptions, and potentially compromising response to imatinib. Berbamine (a bisbenzylisoquinoline alkaloid) has been widely used in Asian countries for managing leukopenia associated with chemotherapy. To investigate whether berbamine shows clinical benefit in reversing imatinib-associated neutropenia, we analyzed 63 chronic-phase CML patients who had developed grade ≥2 neutropenia and were treated with (n = 34, berbamine group) or without (n = 29, control group) berbamine. Among those patients with grade 2 neutropenia, five of 13 (38.5%) progressed to grade 3 neutropenia without berbamine support, while in the berbamine group, the rate decreased to 3/20 (15%) (p = 0.213). Although the rate of recovery from grade ≥3 neutropenia was similar in the two groups (94.1 vs. 90.5%, p = 0.559), berbamine markedly shortened the recovery time (median, 11 vs. 24 days, p = 0.006), and prevented recurrence of grade ≥3 neutropenia (18.8 vs. 52.6%, p = 0.039). Moreover, with berbamine support, the time to achieve complete cytogenetic response was significantly shorter (median, 6.5 vs. 10 months, p = 0.007). There were no severe adverse events associated with berbamine treatment. In conclusion, the present study reveals the potential clinical value of berbamine in the treatment of CML with imatinib-induced neutropenia. The use of berbamine may improve response to imatinib by stimulating normal hematopoiesis and faster neutropenia recovery.

글라백(imatinib)으로 인해 발생한 백혈구 감소증에 한약 투여가 효과가 있다는 내용의 연구입니다.